Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Has Consensus Target Price of $706.87

Key Points

• Analysts rate Madrigal Pharmaceuticals a “Moderate Buy”: 14 of 17 analysts recommend buying, two recommend holding, and one recommends selling. The average 12-month price target is $706.87.
• Quarterly results beat expectations: Madrigal reported EPS of $1.83 versus the consensus estimate of a $1.09 loss, and revenue of $431.27 million compared with estimates of $404.17 million.
• MDGL shares opened at $427.39, below their 50-day and 200-day moving averages. Insiders sold 13,324 shares worth about $7.01 million over the past 90 days; the cited sales were made under pre-arranged plans.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) has received an average rating of "Moderate Buy" from the seventeen analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and fourteen have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $706.87.

Several research firms recently commented on MDGL. Weiss Ratings reiterated a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Canaccord Genuity Group increased their price objective on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. UBS Group restated a "buy" rating and set a $735.00 target price on shares of Madrigal Pharmaceuticals in a report on Wednesday, October 14th. Citigroup lifted their target price on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the stock a "buy" rating in a research report on Tuesday, November 3rd. Finally, The Goldman Sachs Group initiated coverage on shares of Madrigal Pharmaceuticals in a research report on Thursday, September 24th. They set a "buy" rating and a $704.00 target price for the company.

Madrigal Pharmaceuticals Stock Up 0.5%

MDGL opened at $427.39 on Friday. The business's fifty day moving average is $475.72 and its two-hundred day moving average is $495.79. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.78 and a current ratio of 3.05. The company has a market cap of $9.93 billion, a price-to-earnings ratio of -71.47 and a beta of -0.98. Madrigal Pharmaceuticals has a one year low of $353.54 and a one year high of $615.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, beating the consensus estimate of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. The company had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. During the same quarter in the prior year, the company earned ($5.08) earnings per share. Analysts anticipate that Madrigal Pharmaceuticals will post -2.08 EPS for the current fiscal year.

Insider Transactions at Madrigal Pharmaceuticals

In related news, General Counsel Shannon T. Kelley sold 1,077 shares of the company's stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $400.00, for a total value of $430,800.00. Following the sale, the general counsel owned 10,397 shares of the company's stock, valued at approximately $4,158,800. This represents a 9.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Sibold sold 6,362 shares of the company's stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total value of $3,407,423.58. Following the completion of the sale, the chief executive officer directly owned 202,967 shares in the company, valued at approximately $108,707,095.53. The trade was a 3.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 13,324 shares of company stock valued at $7,011,982 in the last ninety days. Corporate insiders own 17.60% of the company's stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Marshall Wace LLP raised its holdings in shares of Madrigal Pharmaceuticals by 75.1% in the third quarter. Marshall Wace LLP now owns 178,350 shares of the biopharmaceutical company's stock worth $89,881,000 after acquiring an additional 76,491 shares during the last quarter. Steward Partners Investment Advisory LLC lifted its position in shares of Madrigal Pharmaceuticals by 37.3% in the third quarter. Steward Partners Investment Advisory LLC now owns 228 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 62 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its position in shares of Madrigal Pharmaceuticals by 6.4% in the third quarter. State Board of Administration of Florida Retirement System now owns 14,898 shares of the biopharmaceutical company's stock valued at $7,508,000 after acquiring an additional 901 shares in the last quarter. AlphaGrep UK Ltd acquired a new stake in shares of Madrigal Pharmaceuticals during the third quarter valued at $324,000. Finally, First Trust Advisors LP boosted its stake in shares of Madrigal Pharmaceuticals by 934.0% during the third quarter. First Trust Advisors LP now owns 204,992 shares of the biopharmaceutical company's stock valued at $103,308,000 after acquiring an additional 185,166 shares during the last quarter. Hedge funds and other institutional investors own 98.50% of the company's stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.